Introduction
Adrenomedullin (AM) is a potent hypotensive and vasorelaxing peptide originally isolated from extracts of human pheochromocytoma tissue (1) . Human AM consists of 52-amino acids with a single disulfide bond and a carboxyl terminal amidation. The peptide is synthesized as a part of a larger precursor molecule, termed preproadrenomedullin, which contains a 20-amino acid amidated peptide, designated proadrenomedullin N-terminal 20 peptide (PAMP). This Elevated circulating AM levels have been identified in cardiovascular, endocrine and renal disorders (6) , and in thrombotic diseases (7) (8) (9) (10) . Therefore AM is probably involved in a wide variety of physiological and pathophysiological conditions, especially in modulating the blood circulation and body fluid balance.
In this short review, we describe the distribution of AMimmunoreactive (IR) cells in human tissues and their related biological properties, and its relation to the biological properties of AM, focusing on the blood coagulation and mucosal defense systems.
Distribution of AM-IR Cells
In our previous study, we first examined the distribution of AM in human, rat, and porcine tissues by using a polyclonal antibody to human AM40-52. This antibody was reactive against AM not only in pheochromocytoma and adrenal medullary cells, but also in pancreatic islets, gastrointestinal neuroendocrine cells, anterior pituitary cells and the choroid plexus, although the immunoreactive intensity varied among species (11) . However, no AM-IR cells were detected in cardiovascular and renal tissues. These results were not compatible with those of the previous biochemical studies (2, 3) . Therefore, using two newly developed and highly sensitive monoclonal antibodies against AM12-25 (a ring structure) and AM46-52 (a native amidated C-terminal) (12), we reinvestigated the distribution of AM in humans, and found that this peptide is widely distributed throughout a wide range of human tissues, as summarized in Table 1 (13) . More intense immunoreactivity was obtained by the use of antibody against AM12-25 than by the use of any of the AM antibodies previously studied. This suggests that the antigenic region containing these amino acid residues is well preserved. In this more recent study, as expected, both cardiovascular tissues and endocrine tissues showed positive-immunoreactivity for AM.
Cardiovascular Tissue
In the heart, almost all myocytes of both the atria and ventricles show an intensely positive reaction. The intensity of AM immunoreactivity is identical between the atria and ventricles (Fig. 1a, b) , but intensely positive AM-IR cells are more frequently noted in the atria. These finding are in agreement with radioimmunoassay data previously reported (3). Cameron and Fleming (14) reported that AM mRNA was expressed relatively uniformly in both the atria and ventricles of rats and mice, while Jougasaki et al. (15) showed that AM immunoreactivity in the atria was more intense than that in the ventricles of dogs. In addition, recent studies have shown that the plasma concentration of AM was increased in patients with congestive heart failure (16, 17) , and that AM immunoreactivity was markedly increased in the failing heart ventricle (18) . AM expression was also shown to be increased in rat hypertrophic ventricles (19, 20) . These findings suggest that AM levels in the heart may be correlated to the degrees of congestive heart failure or cardiac hypertrophy.
In the blood vessels, AM immunoreactivity is observed in medial SMCs of the arteries, veins, and lymphatic channels of varying sizes. Intense immunoreactivity is noted especially in vessels with small walls, or so-called "resistance ves- (13) . sels" (Fig. 1c) . AM dilates resistance vessels in the kidneys, brain, lungs, and hindlimbs of animals. It also augments vasorelaxation of the aorta and cerebral arteries (5) . Plasma AM levels are higher in patients with essential hypertension than in normotensive subjects (21, 22) and are positively correlated with the severity of hypertension (21) . These lines of evidence suggest that AM plays a crucial role in blood pressure regulation.
Several gene-engineering studies have reported that cardiovascular abnormality was observed in AM gene knockout mice (23) (24) (25) . The absence of the AM gene in homozygous mice was lethal to embryos at midgestation because of severe hemorrhage or extreme hydrops fetalis. These findings indicate that AM is essential for cardiovascular development during embryogenesis.
Shear Stress-Dependent Localization of AM
ECs are stained positively for AM, but the intensity is variable and site-dependent. In the aortic arch, AM-positive ECs are present mainly at the branching portions and inner aspect of the curvature (Fig. 2) . This finding suggests that blood flow and/or shear stress modulates AM expression in arterial ECs. Chun et al. (26) reported that AM mRNA expression was dependent on shear stress intensity, and that AM mRNA expression in ECs was higher under condition of high shear stress intensity (15 dyne/cm 2 ) than under low shear stress intensity (5 dyne/cm 2 ). Shinoki et al. (27) , however, demonstrated that much higher shear stress intensity (25 dyne/cm 2 ) suppressed both AM gene transcription and AM peptide levels. As shown in Fig. 2 , AM-IR ECs were observed mainly at relatively low shear stress regions. These findings suggest that AM might participate in the focal modulation of vascular tone induced by hemodynamic shear stress.
Atherosclerotic Lesions
The early stage of human atherosclerosis is characterized by diffuse intimal thickening (DIT), which is composed mainly of SMCs and extracellular matrix. Intimal SMCs in DIT, as well as medial SMCs, show positive immunoreactivity for AM (Fig. 3a) . It is also well known that intimal SMCs have unique properties not found in medial cells, such as high mitotic activity and growth factor receptor expression (28, 29) , and that phenotypes of intimal SMCs are different from those of medial SMCs (30) . Although the functions of AM in intimal SMCs have not been intensively studied, recent studies have reported that AM suppressed the proliferation and migration of cultured SMCs (31) (32) (33) . These results suggest that AM expressed in intimal SMCs could play a preventive role in the progression of atherosclerosis. In fatty streak lesions, which consist of aggregates of foamy macrophages and lower numbers of SMCs, SMCs were stained positive for AM, whereas many foamy cells were negative (Fig. 3b) . In contrast, foamy macrophages in the advanced atherosclerotic lesions show strongly positive immunoreactivity for AM (34, 35) . Macrophages play a crucial role in atherogenesis, and are considered to be highly activated in advanced lesions (30) . Previous studies have demonstrated that cultured macrophages stimulated by lipopolysaccharide (LPS) and interferon-γ produced and secreted AM (4). Macrophagerich lesions have been considered to be rupture-prone areas of atheromatous plaques, which can result in acute coronary syndromes (36) . One study reported that AM inhibited the release of chemoattractants from macrophages (37), suggest-
Fig. 3. Immunohistochemistry for AM in human atherosclerotic lesion. AM immunoreactivity is noted in smooth muscle cells (SMCs) of the intima and media in diffuse intimal thickening (a, 120), SMCs in the fibrous cap of atheromatous lesions (b, 120), and macrophages in advanced lesions (c, 300).

Fig. 2. Whole mount immunostaining for AM in the rat aortic arch. On the luminal surface, AM immunoreactivity is observed at the branching portions and in the inner aspect of the curvature of the aortic arch. Arrow indicates blood flow.
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ing that AM protects against the progression of atherosclerosis and plaque disruption. On the other hand, it has recently been reported that AM may act as an antiapoptotic and growth-promoting factor in vascular SMCs (38) (39) (40) . Further studies will be needed to elucidate the complete functions of AM in atherosclerosis.
Antithrombotic Effects
Blood coagulation is initiated by the binding of plasma protease factor VII/VIIa (FVIIa) to tissue factor (TF). TF is an initiator of the extrinsic blood coagulation pathway. Following activation of factors IX and X, TF serves as a cofactor for coagulation factor VIIa (FVIIa), thereby leading to thrombin generation (41) . Expression of TF in ECs is considered to be one of the major causes of thrombotic disorders, and it is well known that many agents, including LPS and TNF-α, induce TF expression in ECs (41, 42) . The most physiological inhibitor of the TF-FVIIa complex is the tissue factor pathway inhibitor (TFPI), which is a Kunitz domaintype serine protease inhibitor. TFPI directly inhibits factor Xa and induces a feedback inhibition of the TF-FVIIa catalytic complex (43) . ECs are the major source of TFPI. ECs constitutively synthesize and secrete TFPI, and secreted TFPI is exposed on the cell surface via heparan sulfate pro-
teoglycan (HSPG).
Clinical studies have shown that the plasma levels of both AM and TFPI are increased in thrombotic disease, such as acute coronary syndromes, disseminated intravascular coagulation, and thrombosis associated with advanced cancers (7) (8) (9) (10) 43) . These findings raise the possibility of some functional correlations between these molecules in ECs. Recently, Sugano et al. (44) reported that AM attenuated angiotensin-II induced TF expression in rat aortic ECs, mainly via cyclic adenosine monophosphate (cAMP)-mediated pathways. We have also shown that AM inhibited both apoptosis and TF expression of human aortic ECs (45) . Moreover, AM has been shown to augment the synthesis and release of TFPI from human aortic ECs, and this synthesis was partly modulated by cAMP-mediated pathways (46) . We speculate that the AM-induced TFPI release from the EC surface may be dependent on the cationic property of AM, since TFPI binds to cell surface HSPG via the positively charged Cterminal region of the TFPI sequence.
AM induces release of antithrombin (AT) and urokinasetype plasminogen activator (uPA) from the surface of ECs, whereas tissue type plasminogen activator, plasminogen activator inhibitor type 1, and thrombomodulin are not affected by AM (47) .
Taken together, these results suggest that AM may play an important role in the anticoagulant properties of the endothelial surface.
Mucosa and Skin
In the digestive system, AM-IR cells are widely distributed in the mucosal and glandular epithelia of the stomach, esophagus, intestine, gallbladder, bile duct, and acini of the pancreas and salivary glands (13) . In the respiratory system, AM immunoreactivity is observed in the bronchial mucosa, glands, and type II pneumocytes of the lung. In the reproductive system, mucosal and glandular epithelia of the endometrium and endocervix of the uterus have been shown to be positive for AM. Squamous epithelia of the skin, esophagus and uterine cervix have also stained positive for AM. Because the localization of AM is highly similar to that of the defensin family in the mucosa (48, 49) , we suggest that AM may also contribute to the mucosal defense against infection.
Antimicrobial Effect
Our previous immunohistochemical study demonstrated that, in contrast to defensin families that are located in the crypts, AM and PAMP are distributed at the surface portion of the human colonic mucosa (Fig. 4) (50) . By using a colony count assay, both AM and PAMP showed dose-dependent antimicrobial activities against Escherichia coli. The antimicrobial activities of AM and PAMP were comparable to, or superior to, those of human neutrophilic peptide-1 (HNP- 1) and human β-defensin-2 (hBD-2). PAMP showed the strongest antimicrobial activity among the peptides examined ( Fig. 5 ) (50). Allaker et al. (51) reported that AM shows bactericidal activity against Gram-positive and -negative bacterial strains by using disc diffusion and-broth microdilution assays. The concentrations of these peptides showing antimicrobial effects were in the nanomolar range. It still remains unclear whether or not the concentrations in the present study were within the physiological range. However, LPS, several cytokines, and oxidative stress have been shown to markedly enhance AM expression by ECs and SMCs (4, 52) . Accordingly, it may be possible that the local concentrations could become sufficiently high to exhibit antimicrobial activity during infection and inflammation, although up-regulation of AM and PAMP by infection has not been studied in the colonic epithelia in vivo.
Endocrine and Neuroendocrine Tissue
In the adrenal glands, AM-IR cells are observed not only in the adrenal medulla but also in the zona glomerulosa. AM-IR cells are also noted in the pancreatic islets, anterior pituitary glands, and neuroendocrine cells of the gastrointestinal and respiratory systems (13) .
In the gastric mucosa, AM-IR cells are predominantly present in pyloric glands and constitute a subpopulation of gastrin-IR cells (53) . AM-IR cells and gastrin-IR cells decrease in number with the severity of glandular atrophy. We postulate that AM modulates gastrin secretion in the pyloric glands and/or that AM may also play a role in regulation of the mucosal microcirculation.
Inner Ear
Several vasoactive peptides and their receptors, including vasoactive intestinal polypeptide, atrial natriuretic polypeptides, and endothelin, are expressed in the inner ear. This suggests that these peptides are involved in regulation of the inner ear fluid system (54) (55) (56) . More recently, we have revealed that AM mRNA is also expressed in the mouse cochlea, and that AM protein is located in vascular SMCs of the bony labyrinth and vena spiralis modioli and also in the stria vascularis (57) .
AM is considered a member of calcitonin gene-related peptide (CGRP) superfamily (1, 5) . Perivascular CGRP-containing fibers are present along the modiolar vessels and would alter the cochlear blood flow (58) . The interaction of these peptides, AM and CGRP, in the regulation of local vascular tone and blood flow may be an important consideration for cochlear function. The discovery of AM in the stria vascularis suggests that the peptide is directly involved in the endolymphatic water and ionic regulation of this tissue. These results imply a role for AM in the regulation not only of focal hemodynamics but also of cochlear fluid dynamics.
Conclusion and Perspectives
AM-IR cells were widely distributed in human tissues. Multiple biological functions of AM have been intensively studied (5, 6) . Modulation of blood coagulation/fibrinolytic systems, antimicrobial ability in the mucosal defense, and a possible contribution to the auditory system were newly recognized in this study as properties of AM. Further investigations of the characteristics and localization of AM and PAMP receptors will be needed to reveal the physiological roles of these peptides. (47) .
